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A B S T R A C T
Background
Systemic sclerosis is an autoimmune disease characterized by immunological abnormalities,
vascular damage, and fibroblast proliferation. We have previously shown that a molecular
mimicry mechanism links antibodies against the human-cytomegalovirus-derived protein UL94
to the pathogenesis of systemic sclerosis. The UL94 epitope shows homology with NAG-2, a
surface molecule highly expressed on endothelial cells. Anti-UL94 peptide antibodies purified
from patients’ sera induce apoptosis of endothelial cells upon engagement of the NAG-2–
integrin complex.
Methods and Findings
We show here that NAG-2 is expressed on dermal fibroblasts and that anti-UL94 antibodies
bind to fibroblasts. We have used the gene array strategy (Affimetrix oligonucleotide
microarrays) to analyze the transcriptional profile in response to a 4-h and an 8-h treatment
with antibodies against the UL94 peptide in endothelial cells and dermal fibroblasts. Exposure
of endothelial cells to anti-UL94 antibodies had a profound impact on gene expression,
resulting in the upregulation of 1,645 transcripts. Several gene clusters were upregulated
including genes encoding adhesion molecules, chemokines, colony-stimulating factors (CSFs),
growth factors, and molecules involved in apoptosis. Following antibody stimulation, dermal
fibroblasts showed an upregulation of 989 transcripts and acquired a ‘‘scleroderma-like’’
phenotype. Indeed, genes involved in extracellular matrix deposition, growth factors,
chemokines, and cytokines were upregulated. We confirmed the microarray results by real-
time quantitative polymerase chain reaction and by measuring some of the corresponding
proteins with ELISA and Western blotting.
Conclusion
Our results show that anti-human-cytomegalovirus antibodies may be linked to the
pathogenesis of systemic sclerosis not only by inducing endothelial cell activation and
apoptosis but also by causing activation of fibroblasts, one of the hallmarks of the disease.
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Introduction
Systemic sclerosis (SSc) is an autoimmune disease charac-
terized by three main features: (i) structural and functional
vascular abnormalities with perivascular infiltration of
mononuclear inflammatory cells, intimal proliferation, and
luminal narrowing at both the arteriolar and arterial levels,
(ii) immunologic abnormalities, both humoral and cellular,
such as the presence of autoantibodies to intracellular and
cell surface antigens, and perivascular T cell infiltration of
the skin and internal organs, and (iii) excessive extracellular
matrix deposition, leading to fibrosis of the skin and of
internal organs [1].
Autoantibodies directed against intracellular antigens are
associated with SSc and differentiate two distinct clinical
subsets: anticentromere antibodies are found in SSc with
limited cutaneous involvement, while anti–DNA topoisomer-
ase I antibodies are associated with SSc with diffuse
cutaneous involvement [2]. Moreover, autoantibodies direc-
ted against cell surface antigens might induce endothelial cell
damage and apoptosis, considered a primary event in the
pathogenesis of the disease [3,4].
Latent human cytomegalovirus (hCMV) infection may
contribute to progression of SSc through its ability to infect
endothelial cells [5]. Indirect evidence for the association
between hCMV and SSc comes from the prevalence of anti-
hCMV antibodies in patients affected by the disease [6].
Moreover, monoclonal antibodies against topoisomerase I
were found to recognize a pentapeptide of the autoantigen
sharing homology with the hCMV-derived UL70 protein,
suggesting the activation of autoreactive B cell clones by a
molecular mimicry mechanism [7]. Furthermore, some
patients with chronic graft-versus-host disease develop SSc-
like lesions with the presence of typical autoantibodies such
as anti–topoisomerase I [5], and hCMV infection is associated
with an increased risk for the development of chronic graft-
versus-host disease [8]. Finally, murine sclerodermatous graft-
versus-host disease is one of the animal models for human
scleroderma [9,10].
In a previous study we provided direct evidence for a
molecular mimicry mechanism by which antibodies against a
hCMV-derived protein can be linked to endothelial cell
damage in patients with SSc [11]. In the majority of patients’
sera there are antibodies directed against an epitope
(VTLGGAGIWLPP) contained within UL94, a hCMV-derived
protein expressed in infected cells with very late kinetics.
UL94 is localized in the nucleus of infected cells and may be
involved in the regulation of viral and/or cellular gene
expression. The UL94 epitope shows homology with NAG-2
[12], a cell surface molecule highly expressed on non-stressed
endothelial cells and associated with integrins. Affinity
purified anti-UL94 peptide IgG antibodies recognize NAG-2
in a whole cell lysate and induce apoptosis of non-stressed
endothelial cells upon engagement of the NAG-2–integrin
complex [11]. Therefore, we propose that hCMV is linked to
the pathogenesis of SSc through a particular subset of anti-
hCMV antibodies that specifically interacts with a normally
expressed endothelial cell surface receptor sharing similarity
with the UL94 viral protein. The engagement of the receptor
results in endothelial cell apoptosis, considered the primary
pathogenic event in SSc.
Another fundamental feature of SSc is the fibrosis of the
skin and internal organs because of increased extracellular
matrix deposition [13]. Indeed, fibroblasts are thought to play
a major role in the pathogenesis of the disease. They are
directly involved in the synthesis of many extracelluar matrix
components, and the dysregulation of extracellular matrix
turnover is central to fibrosis development in SSc. Sclero-
derma fibroblasts display a variety of phenotypic defects that
range from increased synthesis of multiple matrix proteins to
abnormalities of cell surface receptors and signaling path-
ways [14].
While a direct link between endothelial cell damage in SSc
and hCMV infection has been shown, a correlation between
hCMV and fibrosis is still lacking. In the present study we
wanted to verify whether the NAG-2 receptor is expressed
also on normal fibroblasts and whether the anti-hCMV
antibodies bind normal dermal fibroblasts upon interaction
with the NAG-2 receptor. Moreover, we decided to use a DNA
microarray approach to analyze the effects of these anti-
bodies on endothelial cells and fibroblasts, in order to better
understand the role played by hCMV in the pathogenesis of
the disease. Our findings at gene level were confirmed with
real-time quantitative polymerase chain reaction and with
the analysis of a panel of proteins both in the supernatants of




Eighty-one SSc patients (75 women and six men, mean 6
standard deviation age 54.5 6 14.1 y) from northern Italy
were studied. All patients fulfilled the American College of
Rheumatology criteria for SSc [15]. Sixty of them were
affected by limited cutaneous SSc and 21 by diffuse cutaneous
SSc. Sixty sex- and age-matched individuals without SSc were
used as controls. Blood was obtained from all the patients and
controls after informed written or oral consent.
Peptide Synthesis
The UL94-derived peptide (VTLGGAGIWLLP) and the
irrelevant control peptide (VTLPKDSDVELP)—chosen on
the basis of its absence of relevant homology with the viral
peptide, with the NAG-2 molecule, and with human self-
antigens according to BLASTP via the NCBI BLAST network
service [11]—were synthesized by solid phase synthesis with
the 9-fluorenylmethoxycarbonyl strategy [16].
Purification of Anti-Peptide Antibodies
To affinity purify IgG antibodies against either the UL94
peptide or the control peptide, each peptide (5 mg/g of dried
sepharose powder) was coupled to sepharose 4B (Pharmacia,
Uppsala, Sweden), according to the manufacturer’s instruc-
tions. Pooled sera from ten different patients with SSc were
diluted in PBS. Aliquots of the diluted serum samples were
applied to each column separately. The columns were washed
with PBS. Bound immunoglobulins were eluted with 0.1 M
glycine (pH 2.5) and dialyzed against PBS.
Cell Culture
Human endothelial cells (HUVECs) and human dermal
fibroblast as well as their growth media were purchased from
Promocell Bioscience Alive (Heidelberg, Germany). HUVECs
were used between passages 2 and 5, while dermal fibroblasts
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between passages 3 and 6. Cell monolayers were stimulated
with antibodies affinity purified against the UL94 peptide or
the irrelevant control peptide (20 lg/ml) for various intervals
of time as described in the text. Cell pellets were used for
gene array experiments, while soluble mediators were
measured in the cell supernatants.
FACS Analysis
For FACS (fluorescence-activated cell sorting) analysis, cells
were incubated with specific or control antibodies (5 lg/ml)
for 30 min on ice. Antibody binding was revealed with
fluorescein-isothiocyanate-conjugated anti-human IgG anti-
bodies (SouthernBiotech, Birmingham, Alabama, United
States). Samples were run on a FACScan flow cytometer
(Becton Dickinson, Franklin Lakes, New Jersey, United
States).
Western Blot Analysis
Human dermal fibroblasts were lysed in cold lysis buffer
(0.5% NP-40, 10 mM TRIS [pH 7.4], 0.15 M sodium chloride, 5
mM magnesium chloride), and lysates were immunoprecipi-
tated with rabbit anti-NAG-2 antibodies [11] cross-linked to
sepharose 4B (Pharmacia). Eluted proteins were resolved by
SDS-PAGE and transferred to nitrocellulose membrane
(Amersham Bioscience, Piscataway, New Jersey, United
States). Blots were incubated with either anti-NAG-2 anti-
bodies or human affinity purified anti-peptide antibodies (10
lg/ml). The Renaissance Chemiluminescence Kit (NEN,
Boston, Massachusetts, United States) was used for detection.
Competitive Enzyme-Linked Immunosorbent Assay
Enzyme-linked immunosorbent assays (ELISAs) were car-
ried out as previously described [11,17]. Briefly, for the
binding of antibodies to fibroblasts, affinity purified anti-
hCMV peptide antibodies (10 lg/ml) were diluted in PBS
containing 1% BSA and were incubated for 1 h at 37 8C with
fibroblasts that had been previously fixed with 0.1%
glutaraldehyde. Bound IgG was detected by a further 1 h
incubation with a peroxidase-conjugated antibody against
human IgG (Amersham Bioscience). For the competitive
assay, the amount of antibody that gave 50% of the maximum
binding to fibroblast was preincubated for 1 h at 37 8C with
different amounts of competitors or buffer and then trans-
ferred to the fibroblast-coated plates. The assay was then
carried out as the direct binding assay.
Proliferation Assay
To assess cell proliferation, fibroblasts (5000 cells/well) were
cultured for various intervals of time in microtiter plates in
the presence or absence of antibodies (15 lg/ml affinity
purified antibodies). Cell viability was assessed using the
commercially available kit (Alexis Biochemicals, San Diego,
California, United States).
Preparation of cRNA and Array Analysis
Preparation of cRNA, hybridization, and scanning of probe
arrays were performed according to the protocols of the
manufacturer (Affymetrix, Santa Clara, California, United
States) by the Genopolis Consortium (University of Milano-
Bicocca, Italy) using the Human Genome U133A GeneChip
(Affymetrix). The Human Genome U133A GeneChip is a
single array representing 14,500 well-characterized human
genes and including more than 22,000 probe sets and 500,000
distinct oligonucleotide features.
The different gene expression patterns were analyzed by
using Array Assist version 2.0 (Stratagene, La Jolla, California,
United States), which calculated a robust multi-array average
of background-adjusted, normalized, and log-transformed
intensity values applying the robust multi-array average
algorithm [18,19]. With this software, the mean optical
background level for each array was subtracted from the
signal intensity for each probe. Finally, the normalized,
background-corrected data were transformed to the log2
scale. A signal log2 ratio of 1.0 indicates an increase of the
transcript level by 2-fold change (2 F.C.) and1.0 indicates a
decrease by 2-fold (2 F.C.). A signal log2 ratio of zero would
indicate no change.
In our study, we analyzed the gene expression profiles in
both endothelial cells and fibroblasts stimulated with anti-
bodies affinity purified against the UL94 peptide (test
samples) or with antibodies affinity purified against an
irrelevant peptide (control samples) for 4 and 8 h. Genes
were selected for final consideration when their expression
(F.C.) was at least 2-fold different in the test sample versus
control sample at at least one time point. The microarray
results have been reported according to the MIAME guide-
lines and deposited in the public repository ArrayExpress
(http://www.ebi.ac.uk/arrayexpress; accession number E-
MEXP-382).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted from endothelial cells and
fibroblasts using TRIzol reagent (Invitrogen, Carlsbad, Cal-
ifornia, United States), following manufacturer’s instructions.
One microgram of total RNA from each sample was treated
with amplification grade DNase I and then used as a template
for the reverse transcription reaction, using random hexam-
ers and SuperScript II Reverse Transcriptase (Invitrogen). All
samples were reverse transcribed under the same conditions
and from the same reverse transcription master mix, in order
to minimize differences in reverse transcription efficiency.
Triplicate quantitative real-time polymerase chain reactions
(Q-PCRs) for each sample were performed in 20 ll containing
20 ng of cDNA, 10 ll of 23 Platinum SYBR Green qPCR
SuperMix UDG (Invitrogen), and primers at a final concen-
tration of 200 nM. Table 1 shows the primers used. The Q-
PCR reactions were performed in 96-well plates with optical
caps using the DNA Engine Opticon 2 System (MJ Research,
Waltham, Massachusetts, United States). The reaction con-
ditions were identical for all primer sets as follows: 50 8C for 2
min, 95 8C for 2 min, and then 40 cycles of 95 8C for 15 s and
60 8C for 1 min. Control wells containing no template were
used to exclude the presence of contaminating template
molecules and to identify potential primer–dimer products
from the dissociation curve analysis. Amplification plots were
analyzed using Opticon Monitor version 2.02 (MJ Research),
and data were calculated with QGene (http://www.qgene.org/)
and expressed as mean normalized expression. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was selected as a normaliz-
ing gene according to its stable expression levels.
Cytokines, Chemokines, and Adhesion Molecules
Aliquots of sera and supernatants were frozen at 80 8C
until assayed. The soluble mediators were measured with
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commercially available ELISAs according to the manufac-
turer’s protocol. Measurement below detectable levels was
used as the lower cut-off limit of the assay, according to the
instructions of the manufacturer. The value recorded was the
mean of two measurements. ELISA kits for Vascular
endothelial growth factor (VEGF), Interleukin-6 (IL-6), IL-8,
Transforming growth factor beta 1 (TGF-beta 1), and
Monocyte chemotactic protein 1 (MCP-1) were purchased
from Amersham Bioscience; IL-11, MCP-3, soluble Intercel-
lular adhesion molecule 1 (ICAM-1), soluble E-selectin, and
Vascular cell adhesion molecule 1 (VCAM-1) from R&D
Systems (Minneapolis, Minnesota, United States); Interferon-
gamma-inducible protein 10 (IP10) from Bender MedSystems
(Vienna, Austria); Endothelin 1 (ET-1) from Assay Designs
(Ann Arbor, Michigan, United States); C-terminal Propeptide
of Collagen type I (Pro-Col I) from Quidel Corporation (San
Diego, California, United States); and Epidermal growth
factor (EGF) from Chemicon International (Temecula, Cal-
ifornia, United States).
Gene Ontology Analysis
We performed a Gene Ontology (GO) analysis using Array
Assist version 2.0 (Stratagene).
Statistical Analysis
Statistical testing was performed using StatsDirect (Stats-
Direct, Cheshire, United Kingdom). The significance of
differences between patients and controls was determined
using the unpaired Student’s t-test; p , 0.05 was considered
statistically significant. For sake of clearness the values are
expressed as mean with 95% confidence interval.
Results
Anti-hCMV Peptide Antibodies Bind to Normal Dermal
Fibroblasts
To verify whether anti-hCMV peptide antibodies bind to
human dermal fibroblasts, we performed a FACS analysis
using affinity purified anti-UL94 peptide IgG antibodies and
dermal fibroblasts. As shown in Figure1A and 1B, anti-
peptide antibodies were able to bind dermal fibroblasts. We
also showed that the NAG-2 receptor is expressed on the
surface of dermal fibroblasts and that this molecule is
recognized by anti-hCMV peptide antibodies (Figure 1C).
The specificity of the interaction of such antibodies with the
NAG-2 receptor was further confirmed by a competitive
ELISA that demonstrated that the viral peptide could
displace the binding of the antibodies from the surface of
the dermal fibroblasts (Figure 1D). Since we have previously
demonstrated that anti-hCMV antibodies are able to inhibit
cell proliferation and induce apoptosis of endothelial cells
upon engagement of the NAG-2 molecule [11], we next
wanted to evaluate whether the interaction between the
antibodies and dermal fibroblasts had some functional
consequence for these cells. As shown in Figure 1E, dermal
fibroblasts incubated with the anti-hCMV antibodies prolif-
erated normally, and after 24 and 48 h the rate of
proliferation was slightly higher than for cells incubated with
antibodies against an irrelevant peptide. These data indicate
that anti-hCMV peptide antibodies recognize NAG-2 ex-
pressed on dermal fibroblasts and that this interaction does
not inhibit cell proliferation of the target cells.
Gene Expression Profile in HUVECs Treated with Anti-
hCMV Peptide Antibodies
Since we have already shown that anti-UL94 peptide
antibodies promote endothelial cell apoptosis following
engagement of the NAG-2 molecule [11], we decided to
analyze the gene expression profiles induced in endothelial
cells by the anti-hCMV antibodies in order to identify clusters
of genes known to be involved in the pathogenesis of vascular
damage in SSc.
For this purpose normal endothelial cells were incubated
with either anti-UL94 peptide antibodies affinity purified
from the sera of patients with SSc or with control antibodies
affinity purified against an irrelevant peptide from the sera of
the same individuals. The gene expression profiles were
studied at two different time points: after 4 and 8 h of
stimulation. As stated in Methods, we considered only those
genes expressed more than 2-fold above control at minimally
one time point. Using these criteria, anti-hCMV antibodies
were found to upregulate 1,645 transcripts (Dataset S1)
including genes encoding adhesion molecules, chemokines,
CSFs, growth factors, and molecules involved in apoptosis.
Figure 2 shows an overview of some genes within the above
mentioned clusters. A more detailed representation of the
same genes is presented in compiled form in Table 2, which
includes GeneBank accession numbers and F.C. of expression
of the genes. Among the genes encoding adhesion molecules,
the highest increase in expression was observed for E-selectin,
VCAM-1, and ICAM-1 coding genes (F.C. 68.5, 26.5, and 18.8,
respectively, at 4 h of stimulation) (Table 2). High circulating
levels of these adhesion molecules have been found in
scleroderma [20].
Table 1. Primers Used for Q-PCR
Human mRNA Forward Primer Reverse Primer Accession Number
CCL2/MCP-1 GTCTCTGCCGCCCTTCTGT TTGCATCTGGCTGAGCGAG NM_002982
CXCL8/IL-8 CTGGCCGTGGCTCTCTTG CCTTGGCAAAACTGCACCTT NM_000584
IL-6 GGCACTGGCAGAAAACAACC GCAAGTCTCCTCATTGAATCC NM_000600
GAPDH AACAGCCTCAAGATCATCAGC GGATGATGTTCTGGAGAGCC NM_002046
ICAM-1 Purchased from SuperArraya NM_000201
VCAM-1 Purchased from SuperArray NM_001078
E-selectin Purchased from SuperArray NM_000450
aCompany located in Frederick, Maryland, United States.
DOI: 10.1371/journal.pmed.0030002.t001
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Another cluster of upregulated genes was represented by
genes encoding chemokines (Table 2), a group of cytokines
able to attract leukocytes and regulate angiogenesis, vascular
proliferation, and fibrosis, functions that may contribute to
the manifestations of scleroderma [21]. The expression of
MCP-1 (also called CCL2) was highly increased, with a peak of
74-fold increase in expression at 4 h of stimulation. MCP-1
stimulates fibroblast proliferation and collagen production
[22]. Several other chemokine genes were upregulated in
endothelial cells treated with anti-hCMV peptide antibodies,
such as those encoding MCP-3 (or CCL7), Macrophage
inflammatory protein 1 alpha (MIP-1 alpha [or CCL3]),
Growth regulated oncogene 1 (GRO 1 [or CXCL1]), Stromal
cell-derived factor 1 (SDF-1), and Fractalkine.
Consistent with endothelial damage and activation, an
increased expression of the genes encoding von Willebrand
factor (vWF), Tissue factor (F3), Ephrin A1, and ET-1 was
present in stimulated endothelial cells. Although the increase
in expression of these genes is not specific for SSc, vWF and
F3 molecules are associated with the acquisition of a
Figure 1. Anti-hCMV Antibodies Recognize the NAG-2 Receptor on Dermal Fibroblasts and Do Not Affect Cell Proliferation
(A and B) FACS analysis of the binding of antibodies to normal human fibroblasts: antibodies affinity purified against the irrelevant peptide from sera of
SSc patients (A) and antibodies affinity purified against the UL94 peptide from the same sera (B). Percentage of positive cells is 7% (A) and 83 % (B),
respectively.
(C) Anti-peptide antibodies react with the NAG-2 molecule. Lysates from human dermal fibroblasts were immunoprecipitated with a rabbit affinity
purified anti-UL94 peptide antibody crosslinked to sepharose. Immunoprecipitates were resolved in SDS-PAGE and transferred to nitrocellullose. Blots
were incubated with pre-immune rabbit antiserum (lane 1), rabbit anti-UL94 peptide antibody (lane 2), affinity purified antibodies directed against the
irrelevant control peptide isolated from patients with SSc (lane 3), and anti-UL94 peptide antibodies purified from the sera of the same patients (lane 4).
(D) Binding of affinity purified antibodies against the UL94 peptide to fibroblasts is specifically inhibited by the UL94 peptide (diamonds) but not by an
irrelevant control peptide (circles). Data represent percent of inhibition; inhibitor concentration (horizontal axis) is in micrograms per milliliter.
(E) Fibroblasts incubated with anti-hCMV antibodies normally proliferate. Shown are proliferation levels for fibroblasts incubated for various intervals of
time with medium alone (light grey bars), with affinity purified antibodies directed against the irrelevant control peptide (dark grey bars), or with affinity
purified antibodies against the UL94 peptide (black bars). OD, optical density at 570 nm.
DOI: 10.1371/journal.pmed.0030002.g001
Figure 2. Profile of Selected Genes Modulated in Response to Anti-hCMV Antibodies
Figure shows F.C. in gene expression in endothelial cells (A) and fibroblasts (B) at 4 and 8 h after incubation with affinity purified anti-UL94 antibodies.
Genes are grouped into functional categories based on our current understanding of their function. Genes shown have at least a 2-fold change in gene
expression.
DOI: 10.1371/journal.pmed.0030002.g002
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procoagulant phenotype typical of activated endothelial cells
and Ephrin A1 and ET-1 molecules are associated with
diseases characterized by endothelial dysfunction [23]. Of
note is the upregulation of the gene encoding Angiotensin II
receptor type 1, which plays an important role in ischemia-
induced angiogenesis [24].
Moreover, we found an increased expression of several
genes encoding growth factors (Table 2), including CSFs,
Fibroblast growth factor 2 (FGF-2), Platelet-derived growth
factor (PDGF), and Insulin-like growth factor 2 (IGF-2). These
molecules have also been implicated in the pathogenesis of
SSc; for example, PDGF seems to be associated with fibrotic
damage in SSc [25].
Finally, genes encoding molecules involved in the apoptotic
process, such as TRAMP (DR3), GRIM19, Caspase 1, and
DNAse 1 and 2, were upregulated in accordance with the
observation that endothelial cells undergo cell death follow-
ing incubation with anti-hCMV antibodies [11].
Taken together, these results show that a subset of anti-
hCMV antibodies modulate the expression of a series of gene
clusters encoding molecules playing a fundamental role in the
vascular damage typical of SSc.
Gene Expression Profile in Human Dermal Fibroblasts
Treated with Anti-hCMV Peptide Antibodies
Human dermal fibroblasts were incubated with either anti-
UL94 peptide antibodies affinity purified from the sera of
patients with SSc or with control antibodies purified against
Table 2. Gene Expression in HUVECs after 4 and 8 h of Antibody Stimulation
Category GenBank Accession Number Gene Symbol F.C. 4 h F.C. 8 h Gene Name
Adhesion molecules NM_000201.1 ICAM-1 18.89 3 intercellular adhesion molecule 1
NM_001078.1 VCAM-1 26.5 1.00 vascular cell adhesion molecule 1
NM_003005.2 SELP 2.42 1.4 P-selectin
NM_000450.1 SELE 68.5 1 E-selectin
NM_002060.1 connexin 37 2.62 1.8 connexin 37
Chemokines NM_002982 CCL2 74 6.49 monocyte chemotactic protein 1
NM_002983.1 CCL3 2.49 1 macrophage inflammatory protein 1 alpha
NM_006273.2 CCL7 2.44 1 monocyte chemotactic protein 3
U88321.1 CCL19 3.6 1.00 macrophage inflammatory protein 3 beta
NM_004591.1 CCL20 3.6 1.00 macrophage inflammatory protein 3 alpha
NM_016557.1 CCRL1 3.7 1 chemokine (C-C motif) receptor-like 1
NM_005508.1 CCR4 3 1.00 chemokine (C-C motif) receptor 4
NM_001511.1 CXCL1 2.75 1.00 growth regulated oncogene 1
M57731.1 CXCL2 6.14 1 growth regulated oncogene 2
NM_002090.1 CXCL3 8.75 1.00 growth regulated oncogene 3
NM_000609.3 CXCL12 2.3 3.22 stromal cell-derived factor 1
U84487 CX3CL1 4.5 1 fractalkine
NM_001504.1 CXCR3 2 1.00 CD183
NM_000634.1 CXCR1 2 1 interleukin 8 receptor alpha
NM_001557.1 CXCR2 2 1 interleukin 8 receptor beta
CSFs M11734.1 CSF2 2 1.2 colony-stimulating factor 2
M37435.1 CSF1 2.8 1.6 colony-stimulating factor 1 (macrophage)
BC002635.1 CSF2RA 2.3 1 colony-stimulating factor 2 receptor alpha
Growth factors NM_002006.1 FGF-2 2.41 1.48 fibroblast growth factor 2 (basic)
NM_002608.1 PDGFB 2.56 2 platelet-derived growth factor beta
NM_002607.1 PDGFA 2 1.3 platelet-derived growth factor alpha
M31159.1 IGFBP3 2.2 1.6 insulin-like growth factor binding protein 3
M17863.1 IGF-2 2.3 1 insulin-like growth factor 2
M19154.1 TGFB2 3.36 1 transforming growth factor beta 2
Cell surface receptors NM_000679.1 ADRA1B 3.73 1.00 adrenergic, alpha-1B-, receptor
NM_000750.1 CHRNB4 2.98 1.00 cholinergic receptor beta polypeptide 4
NM_000866.1 HTR1F 2.2 1.18 5-hydroxytryptamine (serotonin) receptor 1F
NM_004835.1 AGTR1 3.11 1.20 angiotensin II receptor type 1
NM_000908.1 NPR3 2.58 1.20 natriuretic peptide receptor C
Apoptosis-related molecules U72763.1 TRAMP 2.23 1.03 death receptor 3
NM_005118.1 TNFSF15 3.53 1 death receptor 3 ligand
NM_003810.1 TNFSF10 5.35 2.31 TRAIL
AF288573.1 TNFSF6 2 1.00 tumor necrosis factor (ligand) 6
U13699.1 CASP1 2.07 1 caspase 1
M55983.1 DNAse 1 2 1.13 DNAse 1
AB004574.1 DNAse 2 2.18 1.79 DNAse 2
NM_01596 5.1 GRIM19 2.67 1.79 gene associated with retinoid-IFN-induced mortality 19
Miscellaneous NM_001955.1 ET-1 5.57 2.73 endothelin 1
BC005956.1 RLN1 3.1 1 relaxin 1
NM_006290.1 TNFAIP3 3.31 1.5 tumor necrosis factor alpha induced 3
NM_004428.1 EFNA1 4.2 2.44 ephrin A1
NM_001993.2 F3 2.3 1 tissue factor (thromboplastin)
NM_000552.2 vWF 1.8 2.00 von Willebrand factor
DOI: 10.1371/journal.pmed.0030002.t002
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an irrelevant peptide from the sera of the same individuals.
The gene expression profiles were studied at the same time
points as for endothelial cells, and we considered for further
analysis only those genes whose expression increased more
than 2-fold above control at at least one time point.
The engagement of the NAG-2 receptor by anti-hCMV
antibodies upregulated 989 transcripts (Dataset S2), including
genes encoding molecules involved in extracellular matrix
deposition, growth factors, chemokines, and cytokines. Fig-
ure 2A shows an overview of a panel of genes within the above
mentioned clusters. A more detailed representation of the
same genes is presented in compiled form in Table 3. An
excessive deposition of collagen and extracellular matrix is
typical of scleroderma fibroblasts and leads to fibrosis of the
skin and internal organs [13]. When compared to control
cells, treated fibroblasts showed increased expression of genes
encoding different types of collagens such as Collagen type I,
type XVI, and type XI (Table 3). Similarly several other genes
involved in extracellular matrix deposition were upregulated
including those encoding Fibronectin, Emilin 1, Dermato-
pontin, Biglycan, Cartilage oligomeric matrix protein, and
Tenascin C with F.C. in expression ranging from 3.53 to 6.82.
Increased levels of the above mentioned proteins have been
associated with SSc [26]. Also, the gene encoding Bone
morphogenetic protein 1 (Procollagen C-proteinase), an
enzyme important for the formation of mature collagens
[27], was upregulated, possibly because of the elevated rate of
collagen synthesis observed in treated fibroblasts. A very high
level of induction was observed for the Hyaluronan synthase
2 gene, with a F.C. in expression of 18.12 at 4 h, which is
compatible with the function of the enzyme in extracellular
matrix metabolism [28].
Analysis of gene expression patterns revealed that the
fibroblasts used in this study also expressed some cytoskeletal
genes encoding proteins typically associated with the myofi-
broblast phenotype (e.g., Transgelin and Elastin) [29]. Anti-
hCMV antibodies also induced the expression of a number of
cytoskeletal genes, which are usually expressed by highly
differentiated smooth muscle cells, such as the gene for
Calponin [29]. Of interest, we also observed induction of the
smooth-muscle-cell-restricted signaling molecule Cysteine
and glycine-rich protein 2 (CSRP2, also known as SmLIM
for smooth muscle LIM-containing protein), which is ex-
pressed in differentiated vascular smooth muscle cells [30].
Overexpression of genes coding for proinflammatory and
profibrotic cytokines (Table 3) has been observed: IL-6, IL-8,
and IL-11, with F.C. in expression of 6.4, 5.54, and 40.78,
respectively, at 4 h. Similarly, genes encoding some chemo-
kines (see Table 2) were upregulated, including MCP-1, MCP-
3, and IP10 with F.C. in expression of 12.9, 4.6, and 12.9,
respectively, at 8 h of stimulation.
Another group of genes included those encoding growth
factors typical of activated fibroblasts, among them TGF-beta
1 and its accessory receptor Betaglycan (TGFBR3) [31], and
Connective tissue growth factor (CTGF), which represent key
mediators of fibrosis in SSc [32]. Interestingly, a series of
genes known to be upregulated in TGF-beta 1–treated
normal fibroblasts [29,33] were found overexpressed in
dermal fibroblasts exposed to anti-hCMV antibodies. This
cluster of genes included those encoding the transcription
factor JUNB, the Smad co-activator Runt-related transcrip-
tion factor 1 (RUNX1), and the transcriptional regulator
TIEG. Most importantly, we found an increased expression of
the signaling molecule Smad7 (F.C. in expression of 8.45 at 4
h of stimulation), known to be overexpressed in scleroderma
fibroblasts [34]. Also, the upregulation of Angiotensin II
receptor type 1 is likely to significantly amplify the
profibrotic actions of TGF-beta 1 [35]. Moreover genes
coding for VEGF, PDGFA, and PDGF receptor B were
overexpressed in treated fibroblasts.
Finally, we observed an increased expression of the gene
coding for Rac protein kinase-beta (Akt), an important
regulator of cell proliferation and survival, and, interestingly,
this gene is overexpressed in scleroderma fibroblasts [36]. The
induction of Akt along with that of two genes involved in
regulating cell growth and apoptosis, IER3 [37] and PIM-1
[38], is consistent with the observation that anti-hCMV
antibodies promote fibroblast survival.
Taken together, these results showed that genes involved in
synthesis of extracellular matrix components and in cell
survival and proliferation were upregulated in fibroblasts
exposed to anti-hCMV antibodies.
Downregulated Genes in Endothelial Cells and Fibroblasts
The engagement of the NAG-2 receptor by anti-hCMV
antibodies downregulated 1,389 genes in endothelial cells and
931 genes in fibroblasts (Datasets S3 and S4). We selected a
few of them, based on their functional relevance.
Table 4 shows a list of repressed genes in endothelial cells.
The gene encoding the anti-apoptotic molecule BCL2 [39]
was highly repressed, in keeping with the observation that
endothelial cells undergo apoptosis following engagement of
the NAG-2 receptor. The decreased expression of the gene
encoding Endothelial nitric oxide synthase (eNOS) has
already been reported in endothelial cells isolated from
patients with SSc, indicating an intrinsic defect in the
mechanism of nitric oxide production [40]. It is worth noting
the downregulation of the Endothelin type B receptor since
this receptor on endothelial cells promotes vasodilatation
through release of nitric oxide and prostacyclin, increases the
clearance of ET-1, and inhibits Endothelin-converting en-
zyme expression [41].
Table 5 summarizes the downregulated genes in fibroblasts.
Interestingly the Death-associated protein kinase 1 (DAPK-1),
a pro-apoptotic protein, was reduced in fibroblasts with a F.C.
in expression of4.47 and7.5 at 4 and 8 h, respectively [42].
Also genes encoding matrix metalloproteinase proteins
(MMP-1, MMP-3, and MMP-10) were reduced especially at 8
h after stimulation. These enzymes are responsible for matrix
degradation and turnover and therefore their reduction may
contribute to the pathogenesis of fibrosis [43,44]. Among the
signal transduction molecules, Smad3, Smad1, and TGF-beta
receptor 2 were downregulated.
Q-PCR Validation of Microarray Results
We performed Q-PCR using the same endothelial and
fibroblast total RNA as was used for the microarray experi-
ments (Figure 3). Overall, the Q-PCR results were concordant
with the array results in six of six genes tested, in terms of
significant differences in expression between cells incubated
with anti-UL94 antibodies and control samples. The genes
subjected to validation included those encoding MCP-1,
ICAM-1, E-selectin, and VCAM-1 in endothelial cells at 4
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and 8 h (Figure 3A) and the genes encoding MCP-1, ICAM-1,
IL-6, and IL-8 in fibroblasts at 4 h (Figure 3B).
GAPDH was selected as endogenous standard, and we saw
no significant changes in the Q-PCR results when the data
were normalized using beta-actin, another constitutively tran-
scribed gene.
Validation of Genes Induced by Anti-hCMV Peptide
Antibodies via Analysis of Soluble Molecules Released in
Cell Supernatants
The analyses of gene expression profiles and Q-PCR were
paralleled by the analysis of some of the corresponding
soluble mediators released by endothelial cells and fibro-
Table 3. Genes Expression in Fibroblasts after 4 and 8 h of Antibody Stimulation
Category GenBank Accession Number Gene Symbol F.C. 4 h F.C. 8 h Gene Name
Collagens M55998.1 COL1A1 1 2.54 collagen type I alpha 1
NM_000094.1 COL7A1 2.63 1.51 collagen type VII alpha 1
J04177 COL11A1 1 5.16 collagen type XI alpha 1
NM_001855.1 COL15A1 1 3.7 collagen type XV alpha 1
NM_001856.1 COL16A1 1.64 2.98 collagen type XVI alpha 1
AY029208.1 COL6A2 1.74 2.28 collagen type VI alpha 2
NM_015719.1 COL5A3 1.21 2 collagen type V alpha 3
Extracellular matrix and
cytoskeletal reorganization
AJ276395.1 FN1 2.6 2.5 fibronectin 1
NM_007046.1 EMILIN1 3.53 4 elastin microfibril interfacer 1
NM_017459.1 MFAP2 1.61 2.3 microfibrillar-associated protein 2
NM_001711.1 BGN 1.00 4.34 biglycan (TGFBR3)
NM_001937.2 DPT 1.13 3.78 dermatopontin
NM_000095.1 COMP 6.82 5.61 cartilage oligomeric matrix protein
NM_005328.1 HAS2 18.12 3.27 hyaluronan synthase 2
U67195.1 TIMP3 2.69 3.13 tissue inhibitor of metalloproteinase 3
M24782.1 ELN 8.9 27.6 elastin
NM_002160.1 TNC 4.59 3.5 tenascin C
NM_006132.1 BMP1 1.6 2.46 bone morphogenetic protein 1 (procollagen C-proteinase)
NM_000602 PAI 2 1 serpin 1
NM_001299 CNN1 2 1.4 calponin (smooth muscle)
NM_003186.2 TAGLN 2 1.95 transgelin (smooth muscle 22 alpha)
NM_001321.1 CSRP2 2.26 3.65 cysteine and glycine-rich protein 2 (SmLIM)
Cytokines and chemokines S69738.1 CCL2 8.1 12.99 monocyte chemotactic protein 1
NM_006273.2 CCL7 3.43 4.6 monocyte chemotactic protein 3
NM_001565.1 CXCL10 1.3 12.9 interferon-gamma-inducible protein 10 (IP10)
NM_002993.1 CXCL6 4.68 26.5 granulocyte chemotactic protein 2
NM_000584.1 IL-8 5.54 3.38 interleukin 8
NM_000600.1 IL-6 6.4 3 interleukin 6
NM_000641.1 IL-11 40.78 4.7 interleukin 11
Growth factors and receptors U48722.1 EGFR 2.09 1.6 epidermal growth factor receptor
M27281.1 VEGF 8.28 4.8 vascular endothelial growth factor
NM_002607.1 PDGFA 2.62 2.2 platelet-derived growth factor alpha
NM_002609.1 PDGFRB 1 2 platelet-derived growth factor receptor beta
M27968.1 FGF-2 4.9 3.2 fibroblast growth factor 2 (basic)
M63889.1 FGFR1 2 2.9 fibroblast growth factor receptor 1
M92934.1 CTGF 2.39 2.1 connective tissue growth factor
TGF beta–related molecules NM_000358.1 TGFBI 2 1 transforming growth factor beta induced
NM_005655.1 TIEG 4 2.5 transforming growth factor beta
inducible early growth response
NM_003243.1 TGFBR3 1.30 2.78 betaglycan
NM_021070.1 LTBP3 1.8 3.27 latent transforming growth factor beta binding protein 3
BC000125.1 TGFB1 2.54 2.56 transforming growth factor beta 1
NM_002229.1 JUNB 2.25 1.32 Jun-B oncogene
NM_001754.3 RUNX1 3.75 2.88 runt-related transcription factor 1
AI568728 SKI 3.48 2.54 v-ski avian sarcoma viral oncogene homolog
NM_005904.1 MADH7 8.45 2.59 smad7
Cell survival and proliferation M77198.1 AKT2 2.75 2.95 rac protein kinase beta
NM_003897.1 IER3 5.38 2 immediate-early response 3
M24779.1 PIM-1 2.12 1.28 PIM-1 oncogene
NM_001657.1 AREG 8.1 1 amphiregulin
NM_000597.1 IGFBP2 1.00 3.29 insulin-like growth factor binding protein 2
NM_000599.1 IGFBP5 1 2 insulin-like growth factor binding protein 5
Miscellaneous NM_007115.1 TNFAIP6 10.77 21.5 tumor necrosis factor alpha induced protein 6
NM_016639.1 TNFRSF12A 5.13 4 tumor necrosis factor receptor superfamily member 12A
NM_000685.2 AGTR1 1.95 4.46 angiotensin II receptor type 1
NM_000201.1 ICAM-1 4.2 11.95 intercellular adhesion molecule 1 (CD54)
DOI: 10.1371/journal.pmed.0030002.t003
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blasts. Table 6 shows the concentration of the molecules
tested in the supernatants of cells incubated with antibodies
against the irrelevant peptide and with anti-UL94 peptide
antibodies. Endothelial cell supernatants were evaluated until
the 24th hour of incubation, at which point apoptosis is
nearly complete. In the supernatant of endothelial cells an
increased concentration of the two chemokines MCP-1 and
MCP-3 could be detected, in accordance with the findings
observed at gene level. Moreover IL-6, IL-8, and TGF-beta 1
concentrations were high at different time points. EGF,
analyzed as a negative control since the expression of the
coding gene was unchanged, was not increased in the
supernatant. In the supernatant of fibroblasts, we detected a
very high concentration of MCP-1. Also, MCP-3 was elevated
at all time points, and IP10 was released at high levels at late
time points. We found increased levels of the interleukins IL-
6, IL-8, and IL-11, reflecting the upregulation of the
corresponding genes. Both TGF-beta 1 and VEGF concen-
trations were increased, and CTGF was detectable by Western
blot. Finally, Collagen type I was secreted at all time points,
indicating that fibroblasts were functionally active and were
secreting constituents of the extracellular matrix, a finding
that is compatible with the phenotype of scleroderma
fibroblasts. These data show that gene overexpression is
paralleled by increased secretion of the corresponding
molecules in the supernatant of stimulated cells.
Analysis of Soluble Molecule Concentrations in the Sera of
SSc Patients
To investigate whether our findings from the gene array
analysis, Q-PCR, and biochemical analysis of the cell super-
natants have a functional correspondance in vivo, we
analyzed the sera of 81 patients affected by SSc. The levels
of IL-6, IL-8, IL-11, ET-1, MCP-1, MCP-3, soluble ICAM-1,
soluble VCAM-1, and soluble E-selectin were detected by
ELISA (Table 7). The levels of IL-6, IL-8, ET-1, soluble ICAM-
Table 5. Downregulated Genes in Fibroblasts after 4 and 8 h of Antibody Stimulation
Category Gene Accession Number Gene Symbol F.C. 4 h F.C. 8 h Gene Name
Apoptosis NM_004938.1 DAPK-1 4.47 7.50 death-associated protein kinase 1
Growth factors BC001422.1 PGF 7.46 2.80 placental growth factor
NM_001147.1 ANGPT2 13.90 11.30 angiopoietin 2
Cell metabolism NM_002421.2 MMP-1 2.11 13.40 matrix metalloproteinase 1
NM_002422.2 MMP-3 1.02 12.60 matrix metalloproteinase 3
NM_002425.1 MMP-10 4.60 5.50 matrix metalloproteinase 10
K03226.1 PLAU 2.54 1.40 preprourokinase
NM_000361.1 ATHBD 2.50 2.80 thrombomodulin
J03225.1 TFPI 2.40 3.00 tissue factor pathway inhibitor
Adhesion molecules M28882.1 MCAM 32.00 24.20 melanoma adhesion molecule
AA702701 PECAM 22.60 18.30 platelet endothelial cell adhesion molecule
NM_016242.1 EMCN 6.00 8.00 endomucin 2
Signal transduction NM_005902.1 MADH3 1.45 2.50 smad3
U54826.1 MADH1 2.20 2.20 smad1
D50683.1 TGFBR2 2.00 2.00 transforming growth factor beta receptor 2
DOI: 10.1371/journal.pmed.0030002.t005
Table 4. Downregulated Genes in HUVECs after 4 and 8 h of Antibody Stimulation
Category GeneBank Accession Number Gene Symbol F.C. 4 h F.C. 8 h Gene Name
Cell proliferation and apoptosis NM_004049.1 BCL2A1 5.6 1.98 BCL2-related protein A1
NM_014739.1 BTF 1.1 2.14 BCL2-associated trascription factor
BC001441.1 SKP2 1.4 2.60 S phase kinase-associated protein 2
AF112857 CCNE2 1.17 2.30 cyclin E2
NM_002915.1 RFC3 1.74 2.2 replication factor C3
Receptors NM_017522.1 LRP8 1.2 2 apolipoprotein E receptor
M35999.1 ITGB3 2.46 5.16 CD61
NM_000610.1 CD44 3.43 1.37 CD44
AI861942 LDLR 2.25 2 low density lipoprotein receptor
NM_003991.1 ETRB 3.92 1.03 endothelin type B receptor
Cell metabolism NM_002130.1 HMGCS1 2.5 4.9 3-hydroxy-3-methylglutaryl-coenzyme-A synthase 1
BC000408.1 ACAT2 1.14 3.2 acetyl-coenzyme A acetyltransferase 2
NM_000603.1 NOS3 3.63 1.28 nitric oxide synthase 3
NM_003326.1 TNFSF4 4.5 1.02 tumor necrosis factor (ligand) superfamily member 4
Transcription factors U12170.1 TCF8 1.83 2.60 transcription factor 8
NM_005966.1 NAB1 1.30 3.24 NAGFI-alpha binding protein
AF220509.1 TAF9L 2.00 3.10 transcription-associated factor TAFII31L
DOI: 10.1371/journal.pmed.0030002.t004
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1, soluble VCAM-1, VEGF, and soluble E-selectin were
significantly higher in patients with SSc than in sex- and
age-matched control individuals. When the limited and the
diffuse forms of the disease were considered, ET-1, MCP-1,
soluble ICAM-1, and soluble E-selectin were significantly
higher in patients with diffuse SSc, whereas soluble VCAM-1
was higher in patients with the limited form of the disease
(Table 8). MCP-3 and IL-11 levels were not different in
patients and controls. These data confirmed the in vitro
findings in vivo for the majority of the molecules analyzed.
Functional Analysis of Gene Expression in Endothelial
Cells and Fibroblasts
GO analysis was used to organize the gene expression data
into their functional relationships based on molecular-level
and biologic processes, and revealed several GO groups that
are of key interest in SSc endothelial cell and fibroblast
pathophysiology. For endothelial cells some of the most
representative groups included cell adhesion, integrin-medi-
ated signaling pathway, and apoptosis, and for fibroblasts the
groups included development and cell proliferation, cell
adhesion, immune response, extracellular matrix organization
and biosynthesis, and muscle development (Tables S1–S4).
Discussion
In the present report we demonstrate that the purified
subset of antibodies directed against the hCMV-derived
protein UL94 bind dermal fibroblasts through the surface
receptor NAG-2. Following this interaction, fibroblasts do not
undergo apoptosis, as endothelial cells do, but proliferate
normally and acquire an activated phenotype resembling the
features of ‘‘scleroderma-like’’ fibroblasts. Therefore, this
subset of anti-hCMV antibodies seems to promote not only
endothelial cell apoptosis, but also fibroblast activation upon
engagement of the same receptor molecule, NAG-2. To
further investigate the effects induced in these two different
cellular targets by the anti-UL94 antibody population, we
used a gene array approach, which allows the simultaneous
detection of thousands of genes in a given sample. By this
approach we found that the purified anti-hCMV antibodies
modulate a vast array of genes encoding molecules that play a
pivotal role in the pathogenesis of SSc.
In endothelial cells some of these genes encode molecules
that are induced under the influence of proinflammatory
cytokines, such as Tumor necrosis factor alpha (TNF-alpha)
and IL-1 [45]. Indeed, genes encoding adhesion molecules
such as ICAM-1, VCAM-1, E-selectin, and P-selectin were
upregulated, and the findings were confirmed by Q-PCR.
These molecules show increased expression on endothelial
cells of SSc skin lesions, and the corresponding soluble forms
are increased in the serum of SSc patients [20,46]. Moreover,
ICAM-1 seems to correlate with the severity of the disease [47]
and E-selectin with the presence of pulmonary fibrosis [48].
We detected a significant increase of these adhesion
molecules both in the supernatant of cultured cells and in
the sera of the patients analyzed.
Figure 3. Validation of Gene Array Results by Q-PCR
Genes selected for validation by Q-PCR in endothelial cells (A) and
fibroblasts (B). MCP-1, ICAM-1, E-selectin, and VCAM-1 transcripts were
increased by 12.89-, 25.36-, 17.59-, and 5.86-fold, respectively, in
endothelial cells incubated with the antibodies for 4 h compared with
control endothelial cells (A). MCP-1, ICAM-1, IL-6, and IL-8 transcripts
were increased 5.7-, 3.44-, 9.54-, and 8.22-fold in fibroblasts incubated
with the antibodies compared to control fibroblasts (B). The level of
transcript expression is reported on the vertical axis. GAPDH was selected
as endogenous gene.
DOI: 10.1371/journal.pmed.0030002.g003
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Significant abnormalities in chemokine expression have
been found in SSc [22,49,50], and, indeed, different chemo-
kine-encoding genes were activated in treated endothelial
cells. The gene encoding MCP-1 presented the highest rate of
activation among all the genes considered. This result was
confirmed by the high increase in MCP-1 transcripts shown
by Q-PCR. MCP-1 plays a pivotal role in the pathogenesis of
SSc, and, indeed, it is expressed at high levels by inflamma-
tory mononuclear cells and endothelial cells in the skin of
patients with SSc of recent onset, suggesting that this
molecule may be involved in the first stages of the disease
[49]. Moreover, elevated levels of MCP-1 are present in
bronchoalveolar lavage cells from SSc patients with lung
involvement, and high serum levels of MCP-1 correlate with
pulmonary fibrosis, suggesting a potential role of this
chemokine in the pathogenesis of lung damage [49]. Also
the gene encoding MCP-3 was upregulated, and, indeed, this
molecule has been found to be elevated in early-stage SSc and
may act as a fibrotic mediator activating extracellular matrix
gene expression in addition to promoting leukocyte traffick-
ing [50]. A similar behavior has been observed for MIP-1
alpha [49,51] and GRO alpha [52]. The chemokine SDF-1 was
also upregulated; since hypoxia is a potent stimulus for SDF-
1, we can hypothesize that during early vascular damage the
hypoxic microenvironment may induce the release of SDF-1,
as demonstrated in another autoimmune disease, rheumatoid
arthritis [53]. And lastly among chemokines, Fractalkine was
highly induced in endothelial cells exposed to anti-hCMV
antibodies (with a fold increase in expression of 4.5 at 4 h of
treatment); this chemokine has been found to be overex-
pressed in endothelial cells of affected skin and in the lung
tissues of patients with SSc. Soluble fractalkine levels were
significantly raised in sera of patients with SSc and were
associated with digital ischemia and severity of pulmonary
fibrosis [54].
Among the other genes found activated, of particular
relevance are the genes that encode ET-1 and PDGF. ET-1 is a
potent vasoconstrictor molecule known to be associated with
Table 6. Soluble Mediators Released in Cell Supernatants
Cell Type Molecule (Units) Incubation Time
4 h 8 h 12 h 24 h 48 h 72 hs
A B A B A B A B A B A B
Endothelial cells IL-6 (pg/ml) 0 0.12 0 1.8 0.48 4.2 1.24 13
IL-8 (pg/ml) 271.57 256.05 649 1,183.3 671.6 1,188.6 1,583.6 2,000
IL-11 (pg/ml) 19.1 19.2 16.1 14.1 16.1 15 16.3 14
TGF-beta 1 (pg/ml) 133.4 187 137.9 296.4 171.4 346.6 317 494.7
MCP-1 (pg/ml) 127.5 323.75 155.83 1,000 187.49 1,995.3 282.5 2,000
MCP-3 (pg/ml) 0.9 2.5 0.9 4.3 0.9 9 0.9 13.2
VEGF (pg/ml) 0 0 0 0 0 0 0 0
EGF (ng/ml) 0 0 0 0 0 0 0 0
Fibroblasts IL-6 (pg/ml) 4.32 14.22 3.24 14.92 3.21 18.51 3.24 34 8.68 58.2 21.4 89
IL-8 (pg/ml) 22 166.7 73.2 327.1 147 1,000 225.2 1,000 534.4 1,000 1,000 1,000
IL-11 (pg/ml) 22.2 22.2 22 42.1 12.9 71 6.3 103.5 1 110.9 1 76.1
TGF-beta 1 (pg/ml) 38 43.6 80 156.5 55.4 80.4 23.7 75.8 37.4 49.8 102.2 138
MCP-1 (pg/ml) 690.91 2,787.5 2,173 5,574.7 2,697.8 7,901.2 3,222.6 10,000 3,966.8 10,000 7,515.8 10,000
MCP-3 (pg/ml) 3.1 16.6 11.8 69.1 9.5 73.6 10.5 279.3 13.6 155.8 21.1 259.2
VEGF (pg/ml) 10 44.3 52.1 231.4 41 211 41.7 206.1 30 113.6 49.5 145.3
Pro-Col I (ng/ml) 99.8 132.7 324.9 360.2 65.1 99.4 307.4 345.7 235.6 340.2 294 389.4
EGF (ng/ml) 0 0 0 0 0 0 0 0 0 0 0 0
‘‘A’’ indicates cells incubated with the control antibody. ‘‘B’’ indicates cells incubated with anti-UL94 antibodies.
DOI: 10.1371/journal.pmed.0030002.t006
Table 7. Soluble Mediator Levels in the Sera of Patients and Controls
Molecule (Units) Patients (n ¼ 81) Controls (n ¼ 60) p-Value
ET-1 (pg/ml) 5.4 (4.8–6.1) 4.1 (3.3–4.9) 0.01
MCP-1 (pg/ml) 641.3 (519.4–763.3) 581.9 (521.7–642) N.S.
MCP-3 (pg/ml) 2.5 (1.8–3.3) 2.2 (1.2–3.2) N.S.
IL-6 (pg/ml) 5.21 (3.2–7.1) 1.19 (0.8–1.5) ,0.001
IL-8 (pg/ml) 17.9 (12.6–23.1) 8.86 (6.9–9.8) 0.004
IL-11 (pg/ml) 2.14 (1.8–2.7) 2.2 (1.8–3.1) N.S.
soluble VCAM-1 (ng/ml) 676.9 (608.5–745.3) 464.9 (431–498.9) ,0.001
soluble ICAM-1 (ng/ml) 288.3 (255.7–320.9) 153.7 (136–171.3) ,0.001
soluble E-selectin (ng/ml) 56.4 (49.1–63.7) 31.6 (28.1–35.1) ,0.001
Data are expressed as mean with 95% confidence interval.
DOI: 10.1371/journal.pmed.0030002.t007
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vascular damage in cardiovascular disease [55]. ET-1 is also
able to induce fibrosis by enhancing collagen synthesis and
inhibiting expression of MMP-1 in skin fibroblasts. Indeed,
ET-1 induces a fibrogenic phenotype in normal fibroblasts
that is similar to that of lesional SSc fibroblasts [56,57]. ET-1
has been extensively studied in patients with SSc who present
high circulating levels of the molecule [58]. The profibrotic
cytokine PDGF plays a major role in stimulating the
replication, survival, and migration of fibroblasts during the
pathogenesis of fibrotic diseases. Moreover, it seems to be
able to induce a significant increase in MCP-1 messenger
RNA and protein in cultured fibroblasts [59]. Finally, the
upregulation of apoptosis-related genes is in accordance with
the reported endothelial cell apoptosis induced by anti-UL94
antibodies.
In fibroblasts, the genes upregulated are mainly involved in
cell activation and proliferation and in the production of
extracellular matrix, all features of scleroderma. In partic-
ular, proinflammatory and profibrotic cytokines such as IL-6
and IL-8 may act synergistically with the chemokines MCP-1
and MCP-3 in recruiting monocytes and leukocytes at the site
of inflammation and acting as fibrotic mediators. The
upregulation of genes encoding IL-6, IL-8, and MCP-1 have
been confirmed by the high increase in the corresponding
transcripts detected by Q-PCR.
MCP-1 and MCP-3 have been shown to be overexpressed in
SSc fibroblasts [22,50]. The production of MCP-1 by
fibroblasts may be mediated by PDGF [59], whose gene is
upregulated in treated endothelial cells and fibroblasts.
Moreover, the gene encoding PDGF receptor B was overex-
pressed in fibroblasts treated with anti-hCMV antibodies, and
it is known that PDGF action is determined by the relative
expression of PDGF receptors on the surface of myofibro-
blasts. These receptors are induced during fibrogenesis,
thereby amplifying the biological responses to PDGF.
The gene encoding the profibrotic cytokine TGF-beta 1 was
also overexpressed. TGF-beta 1 represents a major stimulator
of collagen gene expression through two different signaling
pathways, immediate and delayed [26]. The first one involves
proteins known as Smads that are phosphorylated by
activated TGF-beta receptors, leading to nuclear transloca-
tion and gene transactivation. The second one involves the
induction of secondary matrix stimulatory proteins by TGF-
beta 1, amplifying the initial signal. This activation pathway
involves CTGF [26]. Both Smad- and CTGF-encoding genes
were modulated by the anti-hCMV antibodies in dermal
fibroblasts. TGF-beta 1 may also induce apoptosis resistance
of SSc skin fibroblasts by activating Akt, a kinase of the
phosphoinositide-3-kinase/Akt signaling pathway with potent
anti-apoptotic effects [36]; the resistance to apoptosis of SSc
fibroblasts probably contributes to the accumulation of
activated fibroblasts in the skin, promoting the deposition
of extracellular matrix. Moreover, Akt has been implicated in
cellular transdifferentiation; since TGF-beta 1 has been
implicated in the conversion of fibroblasts to myofibroblasts,
Akt activation may play a role in the increased number of
myofibroblasts that is a key feature of SSc [36]. Moreover, the
phosphoinositide-3-kinase/Akt pathway seems to be impli-
cated in endothelial cell induced smooth muscle cell differ-
entiation [60] also through ET-1 signaling [61]. Finally, EGF
has been recently reported to induce upregulation of TGF-
beta receptor through the phosphoinositide-3-kinase/Akt
signaling pathway [62]. In accordance with characteristics of
SSc, we found upregulation of the genes encoding Akt and
EGF receptor, and of genes typically expressed by smooth
muscle cells, in the fibroblasts exposed to anti-hCMV
antibodies.
Chronic uncontrolled VEGF upregulation seems respon-
sible for the disturbed vessel morphology in the skin of
patients with SSc, and the high serum VEGF levels may be an
indicator of capillary damage in SSc [63,64]. We found both
overexpression of the gene encoding VEGF in cultured
fibroblasts and high circulating levels of VEGF in our
patients. Of particular relevance also is the upregulation of
Angiotensin II receptor type 1 in endothelial cells and in
fibroblasts; this receptor plays a pivotal role in ischemia-
induced angiogenesis and in tissue fibrosis through excessive
production of extracellular matrix components [24,35].
We also tested the level of some chemokines, cytokines,
growth factors, and Collagen type I in the supernatants of
stimulated and unstimulated cells and found that the
concentration of the molecules measured was increased in
the cells incubated with anti-hCMV antibodies, confirming
that gene upregulation is paralleled by the induction of
protein synthesis.
Finally, we measured the serum concentrations of some
cytokines, chemokines, and adhesion molecules in patients
and controls in order to confirm that the genes found
overexpressed in vitro following stimulation with anti-hCMV
antibodies could indeed be of relevance in vivo. We found
that the levels of the majority of these molecules were
significantly higher in patients than in controls, with a
difference between the diffuse and limited subsets of the
disease for some molecules, including MCP-1 and ET-1. A
number of these soluble markers have already been reported
to be increased in the serum of SSc patients [20]. The normal
serum concentration of some other molecules, such as MCP-
3, may be related to the presence of an increased level only in
the damaged tissue, e.g., in the lungs of patients with lung
fibrosis.
In conclusion, our results further support the pathogenic
role of antibodies against the hCMV late protein UL94 in SSc.
We found these antibodies in the vast majority of Caucasian
patients with SSc from northern Italy [11]; the same
antibodies have been detected in both Caucasian and African
American patients, and their concentrations have been
Table 8. Soluble Mediator Levels in the Sera of Patients Affected
by Limited and Diffuse SSc
Molecule (Units) Limited (n ¼ 60) Diffuse (n ¼ 21) p-Value
ET-1 (pg/ml) 5.06 (4.2–5.9) 6.55 (5.5–7.5) 0.04
MCP-1 (pg/ml) 528.6 (460.8–596.3) 934.6 (536-1332.2) 0.04
MCP-3 (pg/ml) 2.8 (1.9–3.6) 2.01 (0.6–3.4) N.S.
IL-6 (pg/ml) 4.44 (2.2–6.6) 7.4 (3.4–11.4) N.S.
IL-8 (pg/ml) 16.2 (12.5–20) 24.7 (11–34.1) N.S.
IL-11 (pg/ml) 2.3 (1.1–7) 1.5 (0.9–5.1) N.S.
soluble VCAM-1 (ng/ml) 716 (268.8–803) 565.2 (487.3–643) 0.01
soluble ICAM-1 (ng/ml) 259.6 (229.3–289.9) 370.3 (282.9–457.7) 0.01
soluble E-selectin (ng/ml) 50.42 (42.7–58.1) 73.6 (57.3–89.9) 0.004
Data are expressed as mean with 95% confidence interval.
DOI: 10.1371/journal.pmed.0030002.t008
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associated with the severity of the disease [65]. We show here
that these anti-virus antibodies are able to induce not only
endothelial cell activation and apoptosis but also fibroblast
activation. They would therefore act as a unifying stimulus
that may explain vascular damage and fibrosis, the two
hallmarks of SSc.
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Patient Summary
Background. Systemic sclerosis, or scleroderma, is the name of a
progressive disease that is characterized by the abnormal growth of
connective tissue and by the narrowing of small blood vessels. It is
triggered when the body’s immune system turns against the body,
causing abnormal production of collagen, which can be limited to the
skin or extend to internal organs. Two types of cells that are involved in
systemic sclerosis are the endothelial cells that line the blood vessels and
fibroblasts, which are involved in the increased fibrosis seen in the skin in
systemic sclerosis.
Why Was This Study Done? Previously these researchers have shown
that one trigger for systemic sclerosis might be antibodies to a protein
from a common human virus, cytomegalovirus, which also reacts with a
molecule on the surface of endothelial cells and causes them to die. The
researchers wanted to look more at this possible mechanism of disease
and work out exactly how these antibodies affected endothelial cells and
fibroblasts.
What Did the Researchers Do and Find? They looked first in cells
cultured in the laboratory to see if the antibody that they had found
previously also stuck to fibroblasts. They found that it did, and that the
attachment of this antibody caused a change in expression of many
genes in both fibroblasts and endothelial cells. For example, in
fibroblasts there was an increased expression of several genes that
code for collagen—which is increased in fibrosis.
What Do These Findings Mean? These findings suggest that an
antibody to a common virus can trigger changes in cells similar to those
seen in systemic sclerosis. Although there are no immediate implications
for treatment, these results may help researchers to understand more
about why systemic sclerosis develops.
Where Can I Get More Information Online? MedlinePlus has many
links to pages of information on systemic sclerosis:
http://www.nlm.nih.gov/medlineplus/scleroderma.html
The Scleroderma Foundation is a nonprofit organization based in the
United States that provides information on scleroderma for patients, and
supports research:
http://www.scleroderma.org/
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